11099 Background: Independent of other factors, p53 status may influence sensitivity to anthracycline (A)- and taxane (T)-based chemotherapy. We investigated p53 as a predictive marker of differential neoadjuvant chemoresponse by examining change in MRI longest diameter (LD) during sequential A- then T-based chemotherapy in a prospective clinical trial. Methods: 171 patients (pts) with newly diagnosed locally advanced breast cancer received neoadjuvant A- then T-based chemotherapy. LD were obtained pretherapy, between regimens, and posttherapy but prior to surgery. P53 mutation analysis was performed on pretherapy tissue using gene chip technology, SSCP, and sequencing. Subtypes were by IHC: LumA (ER/PR+/HER2-), LumB (ER/PR+/HER2+), Basal (triple negative), HER2 (HER2+/ER/PR-). Results: 99 pts had p53 mutant (M) tumors and 72 were wildtype (WT). M and WT did not differ by age, menopausal status, or HER2. M were significantly more common among basal (71%) and HER2 (59%) than Lum A (24%). Anthracycline response did not differ between WT and M within subtypes. Within HER2, Basal, and LumB, WT had higher taxane- and overall responses than M; within LumB these were statistically significant (p=0.03 and 0.05 respectively). Conclusions: P53 mutation status may affect chemosensitivity even within hormone receptor/HER2 subsets. In this dataset response to anthracycline appeared independent of p53 status within subtypes, while WT tumors responded better to taxanes and overall in LumB, with a similar trend among basal and HER2. Mutational subset and correlative analyses with gene expression, molecular subtyping, and IHC data are ongoing and will be presented. [Table: see text] No significant financial relationships to disclose.

BACKGROUND Breast carcinoma is the most common non-skin malignancy in women. More recently, it has been suggested that extracellular proteinase regulates growth factors and cytokines that might contribute to tumour progression. Since CD10 is a cell surface metalloproteinase which inactivates various biologically active peptides, it might facilitate cancer cell invasion and/or metastasis. MATERIALS AND METHODS 48 cases of Invasive Breast Carcinomas were taken up for the study along with 5 cases of benign tumour as a control group (fibro adenoma and phyllodes). Statistical Analysis: For all statistical data chi-square test was applied using IBM SPSS Statistics 20. RESULTS CD10 was found to be positive in 89% (n=43) cases of which 30.3% (n=13) cases showed weak immunoreactivity whereas strong immunoreactivity was observed in 69.7% (n=30) cases. Stromal CD10 expression correlated with well-established prognostic markers, i.e. higher tumour grade (P<0.001), lymph node metastasis (P=0.003), high mitotic rate (P=0.002), increasing NPI (P=0.003), ER negativity (P=0.032), PR negativity (P=0.041) and HER2/neu positivity (P=0.849). CONCLUSION Stromal CD10 expression in Invasive breast carcinomas is closely correlated with invasion and metastasis and it might play an important role in the pathogenesis.

Rhinoscleroma is a chronic granulomatous disease caused by gram negative rod shaped bacteria Klebsiella rhinoscleromatis. Most common sites of predilection include the nasal cavity and nasopharynx, but there are reports of its occurrence at other sites like the larynx, trachea, bronchi, middle ear, and orbit. We are reporting here a case of rhinoscleroma in a middle aged female patient involving the nasal cavity along with a brief review of literature.

1076 Background: At present, effects of heterogeneity among breast cancer subtypes on timing and patterns of relapse are not fully understood. We characterized timing and patterns of distant recurrence among subtypes in women followed from initial diagnosis of breast cancer. Methods: 345 pts with newly diagnosed predominantly stage II-III breast cancer were treated with multiagent neoadjuvant therapy and subtyped by IHC: LumA (ER/PR+, HER2-); LumB (-ER/PR+, HER2+); Basal (triple neg); HER2 (HER2+,ER/PR-). Site-specific patterns of distant metastasis (DM) were examined among pts with single site of first DM. Sites of relapse were bone, CNS, viscera, lymph node, and soft tissue. Time to progression (TTP) was from date of initial diagnosis. Results: 108 patients developed metastatic disease; 65 demonstrated a single site of first DM. Basal subtype was associated with greater CNS and visceral metastases and fewer bone metastases than other subtypes. LumA subtype was associated with fewer CNS and greater bone metastases than other subtypes. [See table]. Dichotomizing as Basal v. non-Basal, bone v. no bone and CNS v. no CNS revealed identical trends with increased significance (p=0.01–0.03). TTP trended toward Basals demonstrating earliest DM and LumA latest. Excluding pts with DM at diagnosis, TTP differed between Basals and non-Basals within viscera (p=0.002, n=14/21, median TTP=10/21); CNS (p=0.047, n=8/7, median TTP=11/27); and bone (p=0.002, n=8/31, median TTP=9/21). Conclusions: Subtypes exhibit distinct timing and patterns of relapse within this largely homogeneous cohort of pts with predominantly locally advanced breast cancer, despite modern multiagent neoadjuvant therapy. Specifically, Basal cancers exhibit earlier recurrence and greater involvement of sites more difficult to treat than non-Basals. Within individual sites TTP differences between Basal and non-Basal tumors persist and are even more pronounced, suggesting that tumor microenvironment does not appear to be driving these differences. [Table: see text] No significant financial relationships to disclose.